Generalisation from phase III clinical trials: survival, quality of life, and health economics
- 1 October 1997
- journal article
- Published by Elsevier in The Lancet
- Vol. 350 (9083) , 1025-1027
- https://doi.org/10.1016/s0140-6736(97)03053-5
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Which patients may be harmed by good treatments?The Lancet, 1996
- Can treatment that is helpful on average be harmful to some patients? A study of the conflicting information needs of clinical inquiry and drug regulationJournal of Clinical Epidemiology, 1996
- Can overall results of clinical trials be applied to all patients?The Lancet, 1995
- Centralised treatment, entry to trials and survivalBritish Journal of Cancer, 1994
- Generalizing the results of randomized clinical trialsControlled Clinical Trials, 1994
- Introduction: From clinical trials to clinical practice—Four papers from a plenary sessionControlled Clinical Trials, 1994
- From clinical trials to clinical practice: Generalizing from participant to patientControlled Clinical Trials, 1994
- Generalizing from clinical trialsControlled Clinical Trials, 1994
- Management of malignant teratoma: does referral to a specialist unit matter?The Lancet, 1993
- Survival of patients with cancer.BMJ, 1989